- BioVaxys Technology (BIOV) has filed a provisional patent application for its viral antigen vaccine platform
- The vaccine is designed to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family Coronaviruses that includes the virus which causes Covid-19
- The company plans to use its vaccine platform to immunize those who have recovered from Covid-19 or who are fully vaccinated against the virus
- BioVaxys Technology is a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics
- BioVaxys Technology Corp. (BIOV) is currently up 15.71 per cent, trading at $0.405 per share
BioVaxys Technology (BIOV) has filed a provisional patent application for its viral antigen vaccine platform.
The vaccine is designed to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of coronaviruses that include the virus which causes Covid-19.
A recent study evaluated those who had a natural immunity to SARS-CoV-1, which first broke out in 2003, and who had received immunization against SARS-CoV-2. The study revealed that those individuals had antibodies to eight other sarbecoviruses in addition to SARS-CoV-1 and SARS-CoV-2.
This cross-reactivity was due to similarities in the S-spike protein. Sarbecoviruses such as SARS-CoV-1 and SARS-CoV-2 all bind to the ACE2 receptor, which makes them highly transmissible.
BioVaxys plans to use its vaccine platform to immunize those who have recovered from Covid-19 or who are fully vaccinated against the virus with a WHO-recognized vaccine.
Dr. David Berd, Chief Medical Officer of BioVaxys, commented,
“Scientists dream of a pan-Coronavirus vaccine that would protect the population against any SARS-like respiratory virus that might mutate and emerge from a wild animal in the future.
“Our approach,” he added, “could constitute a pan-sarbecovirus vaccine that would protect humans against a very dangerous subgroup of Coronavirus that could emerge from the wild and cause as much devastation as Covid-19.”
The company’s novel vaccine is composed of dinitrophenyl (DNP)-modified S-spike protein of SARS-CoV-1. At this time, BioVaxys is not claiming that its vaccine platform has the ability to treat the SARS-CoV-2 virus.
James Passin, CEO of BioVaxys, commented that there are almost 4 billion people who could benefit from this vaccine, once it is developed.
“This total target population,” he said, “represents a massive commercial opportunity for proposed our pan-sarbecovirus booster vaccine, which has the potential to confer cross-reactive neutralizing antibodies, not only against all Covid-19 variants, but future emerging dangerous zoonotic sarbecoviruses.”
BioVaxys Technology is a clinical-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
BioVaxys Technology Corp. (BIOV) is currently up 15.71 per cent, trading at $0.405 per share as of 10:45 am ET.
